Subscribe to RSS
DOI: 10.1055/a-1318-9382
Medikamentöse Therapie der chronisch entzündlichen Darmerkrankungen (CED)
Stand 2020![](https://www.thieme-connect.de/media/klinikarzt/202012/lookinside/thumbnails/10-1055-a-1318-9382-1.jpg)
ZUSAMMENFASSUNG
Die Therapie der chronisch entzündlichen Darmerkrankungen (CED) unterliegt insbesondere in den letzten 2 Jahrzehnten einem deutlichen Wandel. Steroide nehmen in der Behandlung der akuten Entzündung sowohl beim Morbus Crohn als auch der Colitis ulcerosa zwar immer noch einen wichtigen Platz ein, stellen jedoch keine langfristige Therapieoption dar.
Eine Vielzahl neuer galenischer Formulierungen bekannter Medikamente, der Einsatz von Biologika und neuer kleinmolekularer Inhibitoren (mit weiteren Wirkstoffen in der Entwicklung) erweitern die therapeutischen Möglichkeiten erfreulicherweise und führen damit zu einer Verbesserung der Lebensqualität der Patienten.
Die große Herausforderung für den Behandler ist neben der Wahl des geeigneten Medikaments zum richtigen Zeitpunkt, zunehmend auch ein zielgerichtetes Management der Therapie. Hierzu gehören Dosisanpassungen der Therapeutika, geeignete Ko-Medikationen und ein genaues Monitoring des Krankheitsverlaufs.
Publication History
Article published online:
15 December 2020
© 2020. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
Literatur
- 1 Campieri M, Ferguson A, Doe W. et al The Global Budesonide Study Group. Oral budesonide is as effective as oral prednisolone in active Crohn’s disease. Gut 1997; 41: 209-214
- 2 Gomollón F, Dignass A, Annese V. et al ECCO. 3 rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 1: Diagnosis and Medical Management. J Crohns Colitis 2017; 11: 3-25
- 3 Preiß J, Bokemeyer B, Buhr H. et al Aktualisierte S3-Leitlinie – „Diagnostik und Therapie des Morbus Crohn“ 2014 Z Gastroenterol. 2014; 52: 1431-1484
- 4 Torres J, Bonovas S, Doherty G. et al ECCO Guidelines on Therapeutics in Crohn’s Disease: medical Treatment. J Crohns Colitis 2020; 14: 4-22
- 5 Hlavaty T, Krajcovicova A, Payer J. Vitamin D therapy in inflammatory bowel diseases: who, in ≤what form, and how much?. J Crohns Colitis 2015; 9: 198-209
- 6 Townsend C, Parker C, MacDonald J. et al Antibiotics for induction and maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev 2019; 2: CD012730
- 7 Munkholm P, Langholz E, Davidsen M. et al Frequency of glucocorticoid resistance and dependency in Crohn’s disease. Gut 1994; 35: 360-362
- 8 Yarur A, Strobel S, Deshpande A. et al Predictors of Aggressive Inflammatory Bowel Disease. Gastroenterol Hepatol 2011; 7: 652-659
- 9 Colombel J, Sandborn W, Reinisch W. et al SONIC Study Group. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med 2010; 362: 1383-1395
- 10 Colombel J, Sandborn W, Rutgeerts P. et al Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology 2007; 132: 52-65
- 11 Sandborn W, Feagan B, Rutgeerts P. et al Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med 2013; 369: 711-721
- 12 Dulai PS, Singh S, Jiang X. et al The real-world effectiveness and safety of vedolizumab for moderate-severe crohn’s disease: results from the US victory consortium. Am J Gastroenterol 2016; 111: 1147-1155
- 13 Panés J, López-Sanromán A, Bermejo F. et al Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn’s disease. Gastroenterology 2013; 145: 766-774
- 14 Feagan B, Rochon J, Fedorak R. et al Methotrexate for the treatment of Crohn’s disease. The North American Crohn’s Study Group Investigators, N Engl J Med 1995; 332: 292-297
- 15 Hanauer SB, Feagan BG, Lichtenstein G. et al Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-1549
- 16 Feagan BG, Sandborn WJ, Gasink C. et al Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease. N Engl J Med 2016; 375: 1946-1960
- 17 Rubin D, Cohen R, Sandborn W. et al Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial. J Crohns Colitis 2017; 11: 785-791
- 18 D’Haens G. Systematic review: second-generation vs. conventional corticosteroids for induction of remission in ulcerative colitis. Aliment Pharmacol Ther 2016; 44: 1018-1029
- 19 Sandborn W, Su C, Sands B. et al OCTAVE Induction 1, OCTAVE Induction 2, and OCTAVE Sustain Investigators. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med 2017; 376: 1723-1736
- 20 Sands B, Sandborn W, Panaccione R. et al Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med 2019; 381: 1201-1214
- 21 Laharie D, Bourreille A, Branche J. et al Groupe d’Etudes Thérapeutiques des Affections Inflammatoires Digestives. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet 2012; 380: 1909-1915
- 22 Berinstein J, Steiner C, Regal R. et al Efficacy of Induction Therapy With High-Intensity Tofacitinib in 4 Patients With Acute Severe Ulcerative Colitis. Clin Gastroenterol Hepatol 2019; 17: 988-990.e1
- 23 Wang Y, Parker C, Feagan B, McDonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2016; 5: CD000544
- 24 Kruis W, Fric P, Pokrotnieks J. et al Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004; 53: 1617-1623
- 25 Burri E, Maillard M, Schoepfer A. et al Treatment Algorithm for Mild and Moderate-to-severe Ulcerative Colitis. Digestion 2020; 101: 2-25
- 26 Sewitch M, Abrahamowicz M, Barkun A. et al Patient nonadherence to medication in inflammatory bowel disease. Am J Gastroenterol 2003; 98: 1535-1544
- 27 Herfarth H, Barnes EL, Valentine JF. et al Methotrexate Is Not Superior to Placebo in Maintaining Steroid-Free Response or Remission in Ulcerative Colitis. Gastroenterology 2018; 155: 1098-1108
- 28 Ardizzone S, Maconi G, Russo A. et al Randomised controlled trial of azathioprine and 5- ≤aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut 2006; 55: 47-53
- 29 Panaccione R, Ghosh S, Middleton S. et al Combination therapy with infliximab and ≤azathioprine is superior to monotherapy with either agent in ulcerative colitis. ≤Gastroenterology 2014; 146: 392-400
- 30 Kucharzik T, Dignass A, Atreya R. et al Aktualisierte S3-Leitlinie Colitis ulcerosa August 2020 – Konsultationsfassung, AWMF-Registriernummer: 021–009.
- 31 Sands BE, Peyrin-Biroulet L, Loftus Jr. EV. et al Vedolizumab versus Adalimumab for ≤Moderate-to-Severe Ulcerative Colitis. N Engl J Med 2019; 381: 1215-1226
- 32 Macaluso F, Ventimiglia M, Fries W. et al A propensity score weighted comparison of vedolizumab and adalimumab in Crohn’s disease. J Gastroenterol Hepatol 2020 May 19
- 33 Bonovas S, Lytras T, Nikolopoulos G. et al Systematic review with network meta-analysis: ≤comparative assessment of tofacitinib and biological therapies for moderate-to-severe ≤ulcerative colitis. Aliment Pharmacol Ther 2018; 47: 454-465
- 34 Colombel J, D’haens G, Lee W. et al Outcomes and Strategies to Support a Treat-to-target Approach in Inflammatory Bowel Disease: A Systematic Review. J Crohns Colitis 2020; 14: 254-266
- 35 Sulz M, Burri E, Michetti P. et al Treatment algorithms for Crohn´s disease. Digestion 2020; 101: 43-57